Compare XNET & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XNET | PRTC |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 448.1M | 386.7M |
| IPO Year | 2014 | N/A |
| Metric | XNET | PRTC |
|---|---|---|
| Price | $6.77 | $16.91 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 339.1K | 4.8K |
| Earning Date | 11-13-2025 | 08-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 8740.73 | N/A |
| EPS | ★ 20.16 | 0.20 |
| Revenue | ★ $401,918,000.00 | $6,391,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $0.35 | $7.87 |
| Revenue Growth | 27.19 | ★ 1265.60 |
| 52 Week Low | $1.90 | $13.30 |
| 52 Week High | $11.03 | $23.35 |
| Indicator | XNET | PRTC |
|---|---|---|
| Relative Strength Index (RSI) | 37.04 | 51.09 |
| Support Level | $7.06 | $16.44 |
| Resistance Level | $7.46 | $17.17 |
| Average True Range (ATR) | 0.30 | 0.35 |
| MACD | 0.04 | 0.12 |
| Stochastic Oscillator | 13.58 | 55.29 |
Xunlei Ltd is a cloud-based acceleration technology company in China. The company operates a powerful internet platform in China based on cloud computing to provide users with quick and easy access to digital media content through its products and services, Xunlei Accelerator, and cloud acceleration subscription services. It is increasingly extending into mobile devices in part through potentially pre-installed acceleration products in mobile phones Xunlei has developed various value-added services to meet a fuller spectrum of its users' digital media content access and consumption needs.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.